(PharmaNewsWire.Com, May 19, 2020 ) Market growth is largely driven by factors such as the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increased outsourcing of R&D activities, and the increasing number of clinical trials. The introduction of new technologies & methods and growth in the biosimilars and biologics market are expected to provide a wide range of growth opportunities for players operating in this market.
The cardiac safety services market is expected to grow from USD 442 million in 2019 to reach USD 752 million by 2024, at a CAGR of 11.2%
Browse 108 market data Tables and 32 Figures spread through 135 Pages
The integrated services segment to dominate the cardiac safety services market in 2018.
Based on type, the market is categorized into integrated and standalone services. The integrated services segment accounted for the largest market share in 2018. This is primarily attributed to the benefits of bundled services to oversee end-to-end developments, as compared to the specificity of standalone services.
Which is the leading type of service used in cardiac safety services?
The cardiac safety services market is categorized into integrated and standalone services. The integrated services segment accounted for the largest market share in 2018. The large share of this segment can be attributed to the benefits of bundled services to oversee end-to-end developments, as compared to the specificity of standalone services. However, the standalone services cost low as compared to integrated services due to singular nature.
What is the type for cardiac safety services that is widely used and delivery mode?
The cardiac safety services market is categorized into integrated and standalone services. The integrated services segment accounted for the largest market share in 2018. The large share of this segment can be attributed to the benefits of bundled services to oversee end-to-end developments, as compared to the specificity of standalone services. However, the standalone services cost low as compared to integrated services due to singular nature.
The global market is segmented into North America, Europe, the Asia Pacific, and the RoW. In 2018, North America commanded the largest share of the market. This can be attributed to the presence of major pharmaceutical & biopharmaceutical companies and the large number of clinical trials performed in the region.
Key Market Players
The prominent players operating in this market include Biotrial (France), Banook Group (France & Canada), Bioclinica (a subsidiary of Cinven, US), Certara L.P. (US), Celerion, Inc. (US), ERT, Inc. (US), Laboratory Corporation of America Holdings (US), Medpace Holdings, Inc. (US), Ncardia AG (Belgium), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon Inc. (China), Pharmaceutical Product Development LLC (US), SGS S.A. (Switzerland), BioTelemetry, Inc. (US), and IQVIA (US).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
